Donaperminogene seltoplasmid - ViroMed

Drug Profile

Donaperminogene seltoplasmid - ViroMed

Alternative Names: Donaperminogene seltoplasmid; Hepatocyte growth factor gene therapy-ViroMed; Modified hepatocyte growth factor gene therapy-ViroMed; NL003; pCK-HGF-X7; VM-202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RY

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Beijing Northland Biotech; Reyon Pharmaceutical; ViroMed
  • Class Anti-ischaemics; Gene therapies; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Hepatocyte growth factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diabetic foot ulcer; Diabetic neuropathies
  • Phase II Myocardial infarction; Peripheral arterial disorders
  • Phase I/II Amyotrophic lateral sclerosis
  • Phase I Ischaemic heart disorders; Myocardial ischaemia

Most Recent Events

  • 25 Jan 2018 Phase-II clinical trials in Myocardial infarction in South Korea (Intracardiac) (NCT03404024)
  • 01 Jan 2018 Northwestern University and ViroMed initiates enrolment in the HI-PAD trial for Peripheral arterial disorders in USA (NCT03363165)
  • 06 Dec 2017 Northwestern University plans a phase II trial for Peripheral Artery Disease in January 2018 (NCT03363165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top